ArticleRespirology case reports2026
Primary Malignant Melanoma of the Lung With a Long-Term Course: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Malignant Melanoma of the Lung With a Long-Term Course: A Case Report.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 66-year-old man with a 20-year history of recurrent haemoptysis presented with mild bronchiectasis and linear opacities detected on chest computed tomography (CT). The lesion was followed up annually and gradually enlarged into a mass over 10 years. Multiple bilateral pulmonary nodules were noted at 78 years of age. Surgical biopsy revealed malignant melanoma without evidence of other primary lesions on dermatological examination or positron emission tomography-CT. The patient was treated with nivolumab and achieved stable disease for 8 months before discontinuation owing to immune-related adverse events. Rapid disease progression was observed, and the patient died 14 months after initiating immunotherapy. Autopsy demonstrated extensive metastatic dissemination and marked tumour necrosis with CD8+ T-cell infiltration in the lung tumour, indicating a therapeutic response to nivolumab. These findings highlight the potential association between chronic airway inflammation and tumour development and suggest that immunotherapy could play a role in treating PMML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.